Oculis Reports Strong Q1 Results, $277.6M Cash Extends Runway to 2H 2029 Ahead of Key OCS-01 Data
Summary
Oculis Holding AG reported a strong first quarter, increasing its cash position to $277.6 million and extending its cash runway into the second half of 2029, significantly de-risking the company ahead of critical OCS-01 Phase 3 data expected in June.
Key Events
-
Strong Cash Position & Extended Runway
Cash, cash equivalents, and short-term investments increased to $277.6 million as of March 31, 2026, providing a cash runway into the second half of 2029.
-
Successful ATM Offering
The company sold 1,050,000 ordinary shares under its existing At-The-Market (ATM) program, generating gross proceeds of $28.8 million in Q1 2026.
-
Reduced Net Loss
Net loss for Q1 2026 decreased to $36.8 million, compared to $36.9 million in Q1 2025.
-
OCS-01 Phase 3 Progress
Last patient last visit (LPLV) completed for both DIAMOND Phase 3 trials for OCS-01 in diabetic macular edema (DME), with topline results expected in June 2026.
Analysis
The substantial increase in cash and the extended runway to 2H 2029 are highly positive for a clinical-stage biopharmaceutical company, providing significant financial stability and reducing immediate financing concerns. This strong liquidity position supports ongoing clinical development, particularly as the company approaches the critical topline data readout for its OCS-01 Phase 3 trials in June 2026. The successful ATM offering contributed to this strengthened balance sheet, demonstrating the company's ability to raise capital.
At the time of this filing, OCS was trading at $32.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $16.00 to $34.48. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.